TRK fusions

From Libre Pathology
Revision as of 05:53, 11 September 2018 by Michael (talk | contribs)
Jump to navigation Jump to search

TRK fusions are seen in many solid tumours of children and adults and have targeted drugs.[1]

General

Genes

  • TRK1.
  • TRK2.
  • TRK3.

Notes:

  • The TRK genes are tropomyosine kinase receptors.
  • Multiple fusion partners for each gene.
  • Testing: RNA-based next generation sequencing or immunohistochemistry (limited sensitivity).[2]

Classic associations

Drugs

  • Merestinib.
  • Larotrectinib.
  • Others.

See also

References

  1. Drilon, A.; Laetsch, TW.; Kummar, S.; DuBois, SG.; Lassen, UN.; Demetri, GD.; Nathenson, M.; Doebele, RC. et al. (02 2018). "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.". N Engl J Med 378 (8): 731-739. doi:10.1056/NEJMoa1714448. PMID 29466156.
  2. Hechtman, JF.; Benayed, R.; Hyman, DM.; Drilon, A.; Zehir, A.; Frosina, D.; Arcila, ME.; Dogan, S. et al. (Nov 2017). "Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.". Am J Surg Pathol 41 (11): 1547-1551. doi:10.1097/PAS.0000000000000911. PMID 28719467.
  3. Lei, Y.; Chiosea, SI. (Jun 2012). "Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.". Head Neck Pathol 6 (2): 166-70. doi:10.1007/s12105-011-0312-9. PMID 22127547.
  4. Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.